ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01476150
Recruitment Status : Unknown
Verified November 2011 by Guochun Wang, China-Japan Friendship Hospital.
Recruitment status was:  Not yet recruiting
First Posted : November 22, 2011
Last Update Posted : November 23, 2011
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Guochun Wang, China-Japan Friendship Hospital

Brief Summary:
  1. To establish a BMD reference database of Beijing's urban population, China.
  2. To determine the prevalences and risk factors of osteoporosis and osteopenia in Beijing's urban population, China.
  3. To describe the 25OHD level and estimate the prevalence of vitamin D insufficiency and deficiency of Beijing's urban population, China.
  4. Estimation of the prevalence of osteoporotic fracture (vertebral) in over age of 60 of Beijing's urban population, China.

Condition or disease
Osteoporosis

Detailed Description:

With one of the biggest populations in the world, China was heavily suffered from osteoporosis. The prevalence of osteoporosis in China even is increasing fast in recent years, which are especially notable in urban population. This change maybe due to the conditions including rapid economic growth, increase in life expectancy, and changes in lifestyle. Studies in 1998 including 13 separately small samples (no more than 1000 people) from 9 provinces in China showed that the prevalence of osteoporosis and osteopenia were 5.3-6.2% and 5.8-11.2%, respectively. These estimates were higher by approximately 1% than those reported in 1995. In 2002, according to DEXA results in connection with population census in 2000, Xiaoguang Cheng et al. took a survey in 600 people who were separately studied in previously 10 research projects and find that patients with osteoporosis account for approximately 6.97% of the total China population.

Although these studies have documented a remarkable increase in the prevalence of osteoporosis in China, these estimations were all based on small samples. No risk factors related with osteoporosis and osteopenia, esp. hypovitaminosis D on osteoporosis and osteopenia, have been analyzed yet. So it is impossible to make any forecast of osteoporosis or give any instruction for intervention.

Thus this study designed to provide current and reliable data on the prevalence of osteoporosis and osteopenia and associated risk factors correlation coefficients in the Beijing's urban adult population.


Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population
Study Start Date : January 2012
Estimated Primary Completion Date : January 2014
Estimated Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis
U.S. FDA Resources

Group/Cohort
Dongcheng
Haidian
Xicheng
Chaoyang
Chongwen
Tongzhou
Fengtai
Xuanwu



Primary Outcome Measures :
  1. A BMD reference database of Beijing's urban population, China. [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. The prevalences and risk factors of osteoporosis and osteopenia in Beijing's urban population, China. [ Time Frame: 2 years ]

Biospecimen Retention:   Samples Without DNA
complete blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The study will comprise 10,000 people aging from 20 to 79 residing in urban Beijing, China. All of them are members of Beijing Municipal Health Insurance (Beijing is a city that buy medical insurances for all of its residents).
Criteria

Inclusion Criteria:

  • 20 to 79 residents in urban Beijing, China.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01476150


Contacts
Contact: Huiqiong Zhou, MD., PhD. +86-10- 8420 5721 hqzhou@hotmail.com
Contact: Xia Liu, MD., PhD. +86-10- 8420 5721 drliuxia@hotmail.com

Locations
China, Beijing
China-Japan Friendship Hospital Not yet recruiting
Beijing, Beijing, China, 100029
Contact: Xia Liu, MD., PhD.    +86-10- 8420 5721    drliuxia@hotmail.com   
Sponsors and Collaborators
China-Japan Friendship Hospital
Merck Sharp & Dohme Corp.
Investigators
Study Chair: Shukun Yao China-Japan Friendship Hospital

Responsible Party: Guochun Wang, Chief, Dept. of Rheumatology & Immunology, China-Japan Friendship Hospital, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier: NCT01476150     History of Changes
Other Study ID Numbers: CJFSRI-OP
First Posted: November 22, 2011    Key Record Dates
Last Update Posted: November 23, 2011
Last Verified: November 2011

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases